These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 24195245)

  • 21. Factors affecting subjective memory complaints in the AIBL aging study: biomarkers, memory, affect, and age.
    Buckley R; Saling MM; Ames D; Rowe CC; Lautenschlager NT; Macaulay SL; Martins RN; Masters CL; O'Meara T; Savage G; Szoeke C; Villemagne VL; Ellis KA;
    Int Psychogeriatr; 2013 Aug; 25(8):1307-15. PubMed ID: 23693133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vascular disease, Alzheimer's disease biomarkers and cognition in mild cognitive impairment: additive or synergetic effects?
    Nordlund A; Göthlin M; Wallin A
    Dement Geriatr Cogn Disord; 2011; 32(4):250-6. PubMed ID: 22179302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosis and management of Alzheimer's disease: past, present and future ethical issues.
    Gauthier S; Leuzy A; Racine E; Rosa-Neto P
    Prog Neurobiol; 2013 Nov; 110():102-13. PubMed ID: 23578568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Tower of London Test: different scoring criteria for diagnosing Alzheimer's disease and mild cognitive impairment.
    de Paula JJ; Moreira L; Nicolato R; de Marco LA; Côrrea H; Romano-Silva MA; de Moraes EN; Bicalho MA; Malloy-Diniz LF
    Psychol Rep; 2012 Apr; 110(2):477-88. PubMed ID: 22662402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical indications for analysis of Alzheimer's disease CSF biomarkers.
    Engelborghs S
    Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Use of cerebrospinal fluid (CSF) biomarkers for Alzheimer's type dementia: diagnosis in mild cognitive impairment].
    Verhey FR; Visser PJ
    Ned Tijdschr Geneeskd; 2013; 157(11):A5596. PubMed ID: 23484512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Review of recommendations and new diagnosis criteria for mild cognitive impairment due to Alzheimer's disease].
    Allegri RF; Russo MJ; Kremer J; Taragano FE; Brusco I; Ollari JA; Serrano CM; Sarasola D; Demey I; Arizaga RL; Bagnati P
    Vertex; 2012; 23(101):5-15. PubMed ID: 22880190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
    Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
    Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot.
    Hampel H; Lista S; Khachaturian ZS
    Alzheimers Dement; 2012 Jul; 8(4):312-36. PubMed ID: 22748938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is there an MCI reversion to cognitively normal? Analysis of Alzheimer's disease biomarkers profiles.
    Park MH; Han C
    Int Psychogeriatr; 2015 Mar; 27(3):429-37. PubMed ID: 25255915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The biomarker-based diagnosis of Alzheimer's disease. 1-ethical and societal issues.
    Porteri C; Albanese E; Scerri C; Carrillo MC; Snyder HM; Martensson B; Baker M; Giacobini E; Boccardi M; Winblad B; Frisoni GB; Hurst S;
    Neurobiol Aging; 2017 Apr; 52():132-140. PubMed ID: 28317644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contribution of 1H spectroscopy to a brief cognitive-functional test battery for the diagnosis of mild Alzheimer's disease.
    Silveira de Souza A; de Oliveira-Souza R; Moll J; Tovar-Moll F; Andreiuolo PA; Bottino CM
    Dement Geriatr Cogn Disord; 2011; 32(5):351-61. PubMed ID: 22311276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between white matter hyperintensity severity and cognitive impairment according to the presence of the apolipoprotein E (APOE) ε4 allele in the elderly: retrospective analysis of data from the CREDOS study.
    Son SJ; Lee KS; Lee Y; Baek JH; Choi SH; Na DL; Seo SW; Oh BH; Hong CH
    J Clin Psychiatry; 2012 Dec; 73(12):1555-62. PubMed ID: 23146133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasminogen activator inhibitor-1 as an early potential diagnostic marker for Alzheimer's disease.
    Oh J; Lee HJ; Song JH; Park SI; Kim H
    Exp Gerontol; 2014 Dec; 60():87-91. PubMed ID: 25304332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renovating Alzheimer's: "constructive" reflections on the new clinical and research diagnostic guidelines.
    George DR; Qualls SH; Camp CJ; Whitehouse PJ
    Gerontologist; 2013 Jun; 53(3):378-87. PubMed ID: 22936533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of aphasia, apraxia, and agnosia and decline in Alzheimer's disease.
    Yesavage JA; Brooks JO; Taylor J; Tinklenberg J
    Am J Psychiatry; 1993 May; 150(5):742-7. PubMed ID: 8480819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differentiation between amnestic-mild cognitive impairment and early-stage Alzheimer's disease using the Frontal Assessment Battery test.
    Yamao A; Nagata T; Shinagawa S; Nukariya K; Ochiai Y; Kasahara H; Nakayama K
    Psychogeriatrics; 2011 Dec; 11(4):235-41. PubMed ID: 22151243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of the Korean Addenbrooke's Cognitive Examination for diagnosing Alzheimer's dementia and mild cognitive impairment in the Korean elderly.
    Heo JH; Lee KM; Park TH; Ahn JY; Kim MK
    Appl Neuropsychol Adult; 2012; 19(2):127-31. PubMed ID: 23373580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The hard Test Your Memory. Evaluation of a short cognitive test to detect mild Alzheimer's disease and amnestic mild cognitive impairment.
    Brown JM; Wiggins J; Dong H; Harvey R; Richardson F; Hunter K; Dawson K; Parker RA
    Int J Geriatr Psychiatry; 2014 Mar; 29(3):272-80. PubMed ID: 23929807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease.
    Valcárcel-Nazco C; Perestelo-Pérez L; Molinuevo JL; Mar J; Castilla I; Serrano-Aguilar P
    J Alzheimers Dis; 2014; 42(3):777-88. PubMed ID: 24916543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.